Genmab shares double after run of cancer trial wins

Reported by 1 outlet · first reported Nov 3, 4:35 AM ET

Danish biotech Genmab's shares have doubled in three months. The rise follows a string of successful cancer drug trials.

Sources

This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.